. 2022 Sep 14;12:15447. doi: 10.1038/s41598-022-19581-y

Table 2.

Humoral and cellular immune responses during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen.

	Days after first vaccine dose
	Day 1 (n = 100)	Day 15 (n = 100)	Day 29 (n = 97)	Day 61 (n = 97)	Day 82–96 (n = 96)	Day 224–232 (n = 66)	Day 263 (n = 19^§, 14^\|\|)
IgG-S-RBD (AU/mL)	2.6	550*	20582*^†	9649*^‡	5419*^‡	780*^‡	784*^‡
IgG-S-RBD (AU/mL)	(1.43–4.40)	(277–1013)	(11372–29747)	(5168–13143)	(2854–8209)	(439–1345)	(301–1038)
Seropositive (≥ 50)	0%	99%	100%	100%	100%	100%	100%
Seropositive (≥ 4160)	0%	0%	96%	81%	58%	0%	0%
IgG-N (S/C)	0.07	0.07	0.08	0.05	0.07	0.07	0.02
IgG-N (S/C)	(0.02–0.18)	(0.02–0.17)	(0.03–0.19)	(0.02–0.11)	(0.02–0.14)	(0.03–0.14)	(0.02–0.04)
Seropositive (≥ 1.40)	0%	0%	0%	0%	0%	0%	0%
IgM-S (S/C)	0.04	0.79*	2.78*^†	0.75*^‡	–	0.11*^‡	0.15*^‡
IgM-S (S/C)	(0.03–0.08)	(0.45–1.44)	(1.51–4.51)	(0.48–1.52)	–	(0.07–0.29)	(0.08–0.25)
Seropositive (≥ 1.00)	0%	43%	91%	40%	–	3%	0%
IFN-γ CD4⁺ Ag1-Nil (IU/mL)	0.00	0.85*	5.76*^†	1.58*^‡	–	0.42*^‡	0.25*^‡
IFN-γ CD4⁺ Ag1-Nil (IU/mL)	(− 0.01 to 0.01)	(0.37–1.80)	(2.98–11.29)	(0.57–3.22)	–	(0.15–1.32)	(0.08–0.88)
Positive (≥ 0.20)	0%	84%	100%	91%	–	67%	57%
IFN-γ CD4⁺ and CD8⁺ Ag2-Nil (IU/mL)	0.00	1.72*	9.68*^†	2.76*^‡	–	0.91*^‡	0.48*^‡
IFN-γ CD4⁺ and CD8⁺ Ag2-Nil (IU/mL)	(− 0.01 to 0.01)	(0.58–3.17)	(5.38–16.85)	(0.85–6.57)	–	(0.28–1.96)	(0.24–1.78)
Positive (≥ 0.20)	0%	92%	100%	96%	–	88%	86%
NeutraLISA (inhibition %)	–	29*	99*^†	98*^‡	–	–	–
NeutraLISA (inhibition %)	–	(13–45)	(98–100)	(93–99)	–	–	–
Positive (≥ 35)	–	37%	100%	100%	–	–	–

Data are shown as median (interquartile range).

*P < 0.01 (Day 1 vs Day 15, 29, 61, 82–96, 224–232, or 263).

^†P < 0.01 (Day 15 vs Day 29).

^‡P < 0.01 (Day 29 vs Day 61, 82–96, 224–232, or 263).

^§The number of participants tested for humoral responses (IgG-S-RBD, IgG-N, and IgM-S).

^||The number of participants tested for T cell responses (Ag1-Nil and Ag2-Nil).